eConsent Readiness in 12 Countries
eConsent is imperative for continuing research during the COVID-19 pandemic and beyond, but regulations can vary widely across borders. Download this whitepaper to learn the regulatory stances of 12 countries on the use of eSignature and eConsent in clinical trials.
Castor Launches Scalable Patient Enrollment and eConsent Platform to Increase Patient Access and Reduce Recruitment Timelines
Castor’s new eConsent platform will improve remote patient recruitment and enrollment as well as access to diverse populations by decentralizing clinical trials.
Video Conferencing for Remote eConsent: 5 Reasons to Make the Switch
Castor is using video conferencing to meet participant needs and lower site burden in clinical trials. Find 5 benefits here.
How to Prepare an IRB Submission for a Remote eConsent Study
If you are planning on using eConsent in a trial, you’ll need to include it in your IRB submission. Find out what to include here.
Castor Raises $45M Series B to Modernize the Clinical Trial Process and Maximize the Impact of Research Data on Patient Lives
Castor, a leading provider of clinical trial software, announced today the closing of a $45 million Series B financing round with Eight Roads Ventures and F-Prime Capital, bringing the company’s total funding to $65 million.
Understanding the Nuances of Informed Consent in Clinical Trials
Informed consent is a critical aspect of clinical trials. But what criteria must be met? And is there more than one type of consent? Find out here.
Putting PRIDE Into Action at Castor
Castor’s Action Hours during Pride Month gave all Castorians the opportunity to educate themselves and celebrate the LGBTQIA+ culture.
The True Value of eConsent
The future of informed consent is digital. Learn about the benefits, the process, the regulatory landscape, and the future of eConsent here.
Lightship Announces Partnership with Castor to Scale Virtual Clinical Trials Worldwide
Lightship and Castor, leading providers of decentralized clinical trial solutions, today announced a strategic partnership to run direct-to-patient (hybrid) clinical trials at scale.